The absolute knockdown potency of an RNAi agent would determine which fraction of the HBV population fall within this sweet spot. With a 1log knockdown e.g. you could start RNAi with patients with as much as 5000IU/ml.
Thursday, April 23, 2015
Absolute HBsAg Levels, Not Percent Decline May Be Goal of HBV RNAi
The absolute knockdown potency of an RNAi agent would determine which fraction of the HBV population fall within this sweet spot. With a 1log knockdown e.g. you could start RNAi with patients with as much as 5000IU/ml.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
7 comments:
WOW!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
my expection is to lower than 100. or even better 100-1000 times lower than original value
sweet...cant wait
What do the results of Replicor and RGLS mean for the likes of ARWR, TKMR, ISIS, ALNY, BLT, AGX or any other hepatitis chasing company?
More importantly, what are the patent issues, if any, surrounding them? Meaning, whose foundation IP are they employing?
REPLICor...single agent they claim most/all rebound after treatment. In combination, they say all s-seroconvert. There is A LOT of skepticism around REPLICor. One questioner challenged them why they have not published the results 2 years after presenting similar data from the Bangladesh trial at AASLD. Reply was vague and indicated that there were doubts about mechanism of action (e.g. potential innate immune stimulation). So nothing really changed for me, except to see that also in the hepatology community (not only in the oligoRx community) there is this skepticism.
RGLS...it is now about whether RG-101 can enable 4-week pangenotypic treatments. That's always been the base case.
Sounds like another Benetic. All the promises in the world reinforced with some clever PowerPoint slides and devoid of close scientific scrutiny.
I own both ARWR & TKMR. Both companies have acknowledged that to achieve functional cure will require combinational therapy to knock down antigen along with other aspect of infection. I guess it's just matter of who can reach this goal first? Timing wise, isn't ARWR ahead of both TKMR & Replicor?
I'm holding on tight to ARWR & TKMR for now.
Post a Comment